HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Clinical trials for HEPATOCELLULAR CARCINOMA NON-RESECTABLE explained in plain language.
Never miss a new study
Get alerted when new HEPATOCELLULAR CARCINOMA NON-RESECTABLE trials appear
Sign up with your email to follow new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can adding a fourth drug shrink large liver tumors that invade the portal vein?
Disease control Recruiting nowThis trial is testing whether adding hepatic arterial infusion chemotherapy (HAIC) to a combination of lenvatinib, sintilimab, and drug-eluting bead chemoembolization (DEB-TACE) can better control large liver cancers (over 7 cm) that have spread into the portal vein. About 320 pa…
Matched conditions: HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Chemo-loaded microspheres aim to starve liver tumors from within
Disease control Recruiting nowThis trial tests a treatment for people with liver cancer that cannot be removed by surgery. Tiny beads called BioPearl microspheres are loaded with the chemotherapy drug doxorubicin and injected into the blood vessels feeding the tumor. The beads block blood flow and release the…
Matched conditions: HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Phase: NA • Sponsor: Terumo Europe N.V. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo therapy aims to stop liver cancer in its tracks
Disease control Recruiting nowThis study tests whether adding a precise, high-dose radiation treatment (SBRT) after a standard procedure (TACE) can better control liver cancer in people whose tumors cannot be surgically removed. About 30 adults with early- or intermediate-stage liver cancer will receive the c…
Matched conditions: HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Phase: NA • Sponsor: RWTH Aachen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy aims to shrink liver tumors in Hard-to-Treat patients
Disease control Recruiting nowThis study tests a two-step treatment for people with advanced liver cancer that has spread into the main liver blood vessel (portal vein). First, patients receive targeted radiation (SIRT) to shrink the tumor from inside the liver. Then, they get two immunotherapy drugs (durvalu…
Matched conditions: HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Phase: PHASE2 • Sponsor: Center Eugene Marquis • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to boost immune attack on liver tumors
Disease control Recruiting nowThis phase 2 trial is testing whether adding proton radiotherapy to standard immunotherapy (atezolizumab and bevacizumab) can better control advanced liver cancer that cannot be removed by surgery. About 45 participants will receive the combination treatment. The study will measu…
Matched conditions: HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
A new imaging agent could tell doctors which liver cancers will resist immunotherapy
Diagnosis Recruiting nowThis trial is testing whether a special PET/CT scan using 18F-fluorocholine, along with a liquid biopsy, can predict how well patients with inoperable liver cancer (hepatocellular carcinoma) will respond to immunotherapy. The study enrolls adults with this type of liver cancer wh…
Matched conditions: HEPATOCELLULAR CARCINOMA NON-RESECTABLE
Phase: PHASE2 • Sponsor: Queen's Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC